Literature DB >> 18272366

Synthesis and in vitro activity of 1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine and 4-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X7 antagonists.

Alan S Florjancic1, Sridhar Peddi, Arturo Perez-Medrano, Biqin Li, Marian T Namovic, George Grayson, Diana L Donnelly-Roberts, Michael F Jarvis, William A Carroll.   

Abstract

A novel series of aminotriazole-based P2X(7) antagonists was synthesized, and their structure-activity relationships (SAR) were investigated for activity at both human and rat P2X(7) receptors. Most compounds showed greater potency at the human receptor although several analogs were discovered with potent activity (pIC(50) > or = 7.5) at both human and rat P2X(7).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18272366     DOI: 10.1016/j.bmcl.2008.01.095

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

Review 1.  Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.

Authors:  Allen F Brooks; Lindsey R Drake; Megan N Stewart; Brian P Cary; Isaac M Jackson; Dale Mallette; Andrew V Mossine; Peter J H Scott
Journal:  Pharm Pat Anal       Date:  2015-12-16

2.  Discovery of Fused Triazolo-thiadiazoles as Inhibitors of TNF-alpha: Pharmacophore Hybridization for Treatment of Neuropathic Pain.

Authors:  Monika Sharma; Vanamala Deekshith; Arvind Semwal; Dharmarajan Sriram; Perumal Yogeeswari
Journal:  Pain Ther       Date:  2012-09-11

Review 3.  Roles of P2X7 receptor in glial and neuroblastoma cells: the therapeutic potential of P2X7 receptor antagonists.

Authors:  Synthia H Sun
Journal:  Mol Neurobiol       Date:  2010-04-21       Impact factor: 5.590

Review 4.  The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

Authors:  Luiz E B Savio; Paola de Andrade Mello; Cleide Gonçalves da Silva; Robson Coutinho-Silva
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

5.  Selective P2X(7) receptor antagonists for chronic inflammation and pain.

Authors:  William A Carroll; Diana Donnelly-Roberts; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2008-06-21       Impact factor: 3.765

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.